BACKGROUND: Cancer survivors transfused with blood products before reliable screening for hepatitis C virus (HCV) are at risk for infection. This study examined the impact of HCV on neurocognitive function and health-related quality of life (HRQOL) among adult survivors of childhood cancer. METHODS: Neurocognitive testing was conducted for 836 adult survivors of childhood cancer (mean age, 35 years [standard deviation, 7.4 years]; time since diagnosis, 29 years [standard deviation, 6.2 years]) who received blood products before universal HCV screening. No differences were observed between confirmed HCV-seropositive survivors (n 5 79) and HCV-seronegative survivors (n 5 757) in the primary diagnosis or neurotoxic therapies. Multivariate regression models were used to compare functional outcomes between seropositive and seronegative survivors. RESULTS: Compared with seronegative survivors, seropositive survivors demonstrated lower performance on measures of attention (P < .001), processing speed (P 5 .008), long-term verbal memory (P 5 .01), and executive function (P 5 .001). After adjustments for sex, age at diagnosis, and treatment exposures, seropositive survivors had a higher prevalence of impairment in processing speed (prevalence ratio [PR], 1.3; 95% confidence interval [CI], 1.1-1.6) and executive functioning (PR, 1.3; 95% CI, 1.1-1.6). Differences were not associated with the treatment of HCV or the presence of liver cirrhosis. Seropositive survivors reported worse general HRQOL (PR, 1.6; 95% CI, 1.2-2.1), which was associated with the presence of liver cirrhosis (P 5 .001). CONCLUSIONS: Survivors of childhood cancer with a history of HCV infection are at risk for neurocognitive impairment and reduced HRQOL beyond the known risks associated with neurotoxic cancer therapies. Cancer 2017;123:4498-505.
INTRODUCTION
The 5-year survival rate for patients with childhood cancers in the United States has increased over the last 4 decades to approximately 80%. 1, 2 Studies suggest that a sizable percentage of survivors will experience neurocognitive impairment in at least 1 cognitive domain. [3] [4] [5] [6] The survivors at greatest risk are those exposed to cranial radiotherapy (CRT), intrathecal or high-dose intravenous methotrexate, or neurosurgery. 7, 8 Blood products are often required during cancer-directed therapy, and this may result in exposure to blood-borne pathogens such as hepatitis C virus (HCV). In the 1970s and 1980s, before reliable screening for HCV, transfusionrelated HCV infections were the number 1 source of HCV infections within the general population, and the risk rates were estimated to be 5% to 18% 9, 10 The development of the first-generation enzyme-linked immunosorbent assay and recombinant immunoblot assay in 1989 and the development of the second-generation enzyme-linked immunosorbent assay in 1992 improved blood screening, and posttransfusion hepatitis infection rates fell to 0.57%. 11, 12 Today, injection drug use is the number 1 risk exposure/behavior associated with HCV infection. 13 Although the risk of transfusionrelated infection is low for newly diagnosed cancer patients, thousands of patients with cancer or aplastic anemia were treated before widespread screening, with 7348 patients treated at St. Jude alone.
14 Many of these patients were at risk for contracting HCV from potentially tainted blood products. It is this population that is the focus of our study.
In the general population, 80% of those with an acute HCV infection develop a chronic HCV infection. 15, 16 In addition to liver fibrosis or cirrhosis, 17 neurocognitive dysfunction has been reported in nearly 50% of individuals with chronic HCV. [17] [18] [19] [20] [21] Imaging of chronic seropositive individuals has revealed metabolic and macrostructural changes in the white matter and deep gray matter regions of the frontal cortex, which have been found to correlate with increased fatigue and cognitive impairment. In addition, central nervous system inflammation and neuronal damage have also been noted among chronic individuals. 18, 19 Greater severity of liver disease has been associated with poorer neurocognitive functioning; however, HCV infection has been associated with an increased risk of dementia in those who have not yet progressed to liver cirrhosis. 20 The combined physical and neurocognitive complications associated with HCV affect health-related quality of life (HRQOL). HCV individuals report more fatigue, health-related concerns, and pain interfering with daily activities/functioning. [21] [22] [23] Treatments for HCV include antivirals such as interferon and ribavirin, which have been linked to mood dysregulation and may further exacerbate HCV-related fatigue and cognitive difficulties. 24 Some researchers, however, suggest that some degree of cognitive rebound is evidenced in HCV patients treated with interferon and ribavirin 12 months after viral eradication. 25, 26 The unique contribution of HCV infection to neurocognitive function in cancer survivors has not been reported. The purpose of the current study was to examine this association in a large sample of adult survivors of childhood cancer. Specifically, we aimed to determine 1) whether HCV-seropositive survivors have greater deficits in verbal memory, attention, processing speed, and executive functioning in comparison with HCV-seronegative survivors and 2) whether HCV-seropositive survivors report lower HRQOL in comparison with HCVseronegative survivors.
MATERIALS AND METHODS

Participants
Eligible participants included adult survivors of childhood cancer enrolled in the St. Jude Lifetime (SJLIFE) cohort study, treated at St. Jude Children's Research Hospital, and exposed to blood products before July 1992 (when HCV screening using the second-generation enzymelinked immunosorbent assay was initiated). The methods of SJLIFE have been previously described by Hudson et al. 27 Survivors were excluded if they had a genetic, neurodevelopmental, or neurologic condition unrelated to cancer or cancer therapy (eg, cerebral palsy or traumatic brain injury) or were not proficient in English. According to a medical record assessment, 1304 survivors received blood products during treatment before 1992; 200 of these survivors (15%) did not complete neurocognitive testing because they were not eligible for a risk-based neurocognitive referral at the time of their most recent SJLIFE visit (n 5 171), declined participation (n 5 28), or were unevaluable on account of extremely low cognitive functioning (n 5 1). Radiation dosimetry was unavailable for an additional 264 patients (20%), and the HCV status was unknown for 4 survivors. The final cohort consisted of 836 adult survivors (64.1%). This study was approved by the institutional review board, and all participants provided written informed consent.
Procedure
Cancer treatment data were abstracted by medical record review and included the cumulative doses of specific chemotherapeutic agents and radiation treatment fields and doses. Survivors also underwent physical examinations during long-term follow-up visits. The HCV status was determined by a combination of the second-generation enzyme-linked immunosorbent assay and the secondgeneration recombinant immunoblot assay or polymerase chain reaction; 79 survivors (9.4%) were confirmed as seropositive, and 757 (90.6%) were confirmed as seronegative. The HCV prevalence within our sample was consistent with estimated treatment-related infection rates before 1992. 9, 10, 28 For survivors who were seropositive, medical records were independently reviewed by 2 pediatric oncologists so that liver cirrhosis would be graded in a manner consistent with the Common Terminology Criteria for Adverse Events (version 4.03). 29 Only grade 3, defined as compensated, biopsy-proven liver cirrhosis (ie, the survivors did not have symptoms related to cirrhosis), and grade 4, defined as decompensated, biopsy-proven liver cirrhosis (eg, the survivors had symptoms related to hepatic insufficiency or portal hypertension), were considered. An analysis of HCV treatment effects on neurocognitive measures among the HCV-seropositive participants was conducted. Of the 79 HCV-seropositive participants in this study, only 62 had their HCV treatment data available. Therefore, the related analysis was limited to those who had HCV treatment data (n 5 62).
Neurocognitive testing was conducted during a single 2-hour visit by licensed/certified examiners under the general supervision of a board-certified clinical neuropsychologist as outlined in the SJLIFE cohort study (the study methodology was previously published). 27, 30 Assessed cognitive domains are outlined in Supporting Table 1 (see online supporting information) and included the following: intelligence, 31 executive function, [32] [33] [34] verbal memory, 32, 35 attention, [32] [33] [34] 36 and processing speed. 32, 36 The order of testing was standardized, and survivors' schedules were adjusted to limit the impact of fatigue and extraneous factors. Survivors completed the Medical Outcomes Study 36-Item Short Form Health Survey 37 to evaluate perceived HRQOL. The 36-Item Short Form Health Survey includes 2 overall composites (physical and mental), each of which is composed of 4 subscales.
Statistics
Demographic and clinical characteristics were compared between seropositive and seronegative survivor groups with t tests or chi-square tests as appropriate. Neurocognitive and HRQOL measures were converted to age-adjusted z scores (mean, 0; standard deviation, 1) with populationnormative data. Two-sample t tests were used to compare z scores between HCV-seropositive and HCV-seronegative survivors, with family-wise error rate correction for multiple comparisons within each neurocognitive and qualityof-life domain. Neurocognitive impairment was identified within the domain (ie, attention, verbal memory, processing speed, and executive functioning) and was defined as having at least 1 measure within the domain with a z score less than -1.33; this corresponded to the bottom 10% of the general population. Impairment for HRQOL scores was defined as a z score less than -1.00, which was consistent with developer guidelines. 31 The prevalence of neurocognitive and HRQOL impairment in seropositive survivors versus seronegative survivors was compared with multivariate Poisson regression models with robust error variances. The models and the subsequent secondary analysis were limited to those neurocognitive and HRQOL variables identified in the 2-sample t test comparison of z scores with a P value .01. Models were adjusted for sex, age at diagnosis, and select treatment exposures (ie, chemotherapy, cranial radiation, and chest radiation). No significant differences were noted in the demographics between the HCV-treated and untreated groups; therefore, the demographics were not adjusted for the comparison of neurocognitive outcomes between the treated and untreated groups.
RESULTS
The mean age at evaluation was 35 years (standard deviation, 7.4 years), and the sample was predominantly non- Hispanic white (89%) and female (52%). The mean age at diagnosis was 6 years (standard deviation, 4.8 years), and the mean time since diagnosis was 29 years (standard deviation, 6.2 years). Forty-two percent of the sample received high-dose CRT (20 Gy). No differences were observed between seropositive (n 5 79) and seronegative participants (n 5 757) in race, sex, CRT dose, chest radiation dose, or exposure to antimetabolites or alkylating agents ( Table 1 ). The seropositive participants were found to be slightly older at assessment (age for seropositive participants, 37.5 years; age for seronegative participants, 34.9 years; P 5 .003) and had a slightly longer time since diagnosis (time for seropositive participants, 30.5 years; time for seronegative participants, 29.0 years; P 5 .04).
In comparison with seronegative survivors, seropositive survivors demonstrated lower performance on measures of verbal (P 5 .04) and perceptual ability (P 5 .02; Table 2 ). Seropositive survivors demonstrated significantly lower performance on a measure of cognitive flexibility (seropositive mean, -1.62; seronegative mean, -0.86; P 5 .001) in comparison with both seronegative survivors and the normative sample. Significant differences were also noted between groups in measures of verbal fluency (P 5 .02), new verbal learning (P 5 .04), long-term verbal recall (P 5 .01), verbal memory span (P 5 .016), focused attention (P 5 .0009), visual processing speed (P 5 .02), and visual-motor processing speed (P 5 .008). Seropositive survivors also reported worse HRQOL than seronegative survivors, particularly with respect to physical role limitations (P 5 .008) and general health (P 5 .001). It was noted that, with the exception of cognitive flexibility, the mean performance within both groups generally fell within the average to low average range. However, the seropositive group was found to have significantly more individuals whose performance fell at or below the bottom 10% of the normative population.
In multivariate models examining neurocognitive function and adjusted for sex, age at diagnosis, and key In multivariate models examining HRQOL (Table  4) , seropositive survivors had a 55% higher prevalence of impaired general health (PR, 1.55; 95% CI, 1.17-2.06) in comparison with seronegative survivors. A history of high-dose chest radiation 30 Gy was also associated with an increased prevalence of self-reported physical role limitations (PR, 1.87; 95% CI, 1.14-3.08) and poor general health (PR, 1.92; 95% CI, 1.29-2.86).
Among the seropositive survivors, the presence of liver cirrhosis was associated with poor HRQOL but not neurocognitive function (Table 5 ). Specifically, cirrhosis was associated with a worse general health status (P 5 .001). Among the seropositive survivors, no significant differences were noted in the neurocognitive performance or self-reported HRQOL between those treated and those untreated for HCV. Among the neurocognitive outcomes, only one was marginally different between the treated and untreated groups (P 5 .07 for long-term verbal recall; Supporting Table 2 [see online supporting information]).
DISCUSSION
Our findings suggest that HCV-seropositive adult survivors of childhood cancer have an increased prevalence of neurocognitive problems and poor HRQOL. Although only performance on a cognitive flexibility task fell significantly below normative expectations, the mean performance was significantly lower for the HCVseropositive group versus the seronegative group on most tasks. In addition, significantly more individuals within the HCV-seropositive group exhibited performance falling within the problem range (ie, a z score < -1.00). This increased prevalence of impairment was further supported by the multivariate findings. Seropositive Abbreviations: CI, confidence interval; HCV, hepatitis C virus; PR, prevalence ratio. Impairment was based on at least 1 score within each domain falling below the 10th percentile of population norms. The risk associated with the age at diagnosis and the time since diagnosis is presented as per year. Bolded values are significant.
survivors had reduced performance on measures of executive functioning and processing speed. An HCVseropositive status was associated with an increased prevalence of poor physical health and general HRQOL, with those patients receiving high-dose chest radiation reporting the greatest difficulties.
In agreement with previous reports, the presence of liver cirrhosis was not associated with neurocognitive function, although it was associated with reports of lower general health. This finding suggests that damage to the central nervous system and brain structures from chronic HCV may occur well before measurable organ damage can be noted. Finally, among seropositive survivors who received HCV treatment, no significant differences were noted in overall performance on neurocognitive measures or on self-reporting of HRQOL, and this suggests that an adult cancer survivor population may not benefit from the purported cognitive rebound observed within some noncancer general population samples.
The mechanism of neurocognitive and quality-oflife impairment by HCV is unclear, but in many ways, the biologic effects resemble the effects of cancer treatments. In noncancer HCV-seropositive individuals, it is theorized that infected monocytes disseminate HCV to the central nervous system, and this results in inflammation and neuronal damage. This further results in the changes in the white matter and deep gray matter regions of the frontal cortex that can be observed with imaging. 18, 19 These imaging outcomes in the general population are Abbreviation: SD, standard deviation. Scores are presented as age-adjusted z scores (population mean, 0; SD, 1.0). The P values are based on a 2-sample t test. Inclusion in the analysis was limited to cognitive variables identified in Table 1 with P values .01. a The bolded value is significant. similar to those observed in adult survivors of acute lymphoblastic leukemia, 38 and they correspond to the neurocognitive deficits reported in this article and in previous reports of adult survivors of childhood acute lymphoblastic leukemia. 39, 40 Neurocognitive function and HRQOL in adult survivors of childhood cancer may be more sensitive to the additional neurotoxic effects of chronic HCV. Our findings indicate that both seropositive and seronegative adult survivors demonstrated reduced performance in comparison with a normative sample with respect to the percentage of the sample falling within the impaired range. In addition, seropositive survivors performed significantly worse than seronegative survivors on most tasks. Likewise, on a self-reported measure of quality of life, the seropositive survivors endorsed significantly more physical role limitations and general health concerns than both the normative sample and the seronegative survivors.
The findings from our study should be interpreted with a recognition of its limitations. Our outcomes were assessed cross-sectionally, and thus we were unable to address the potential time-varying effects of HCV on neurocognitive and quality-of-life outcomes. Because of the absence of reliable and systematic screening for HCV before 1992, the current study could not control for the age of HCV exposure or the time since HCV exposure. However, it is likely that the greatest risk of HCV exposure occurred during the course of cancer treatments, 17, 41 and both the age of the cancer diagnosis and the time since the cancer diagnosis have been considered in the current study. The impact of HCV treatment on acute/postacute neurocognitive function was not directly examined at this time; however the overall HCV treatment history was examined, and no significant differences were noted among those treated and those not treated for HCV. Lastly, although no substantive differences were observed between SJLIFE participants and nonparticipants, 30 our analysis was restricted to a specific subset of SJLIFE participants who underwent an in-person neurocognitive assessment. Nonparticipants were composed of survivors with a lower risk of neurocognitive impairment based on cancer-directed therapy. If these nonparticipants also had a lower frequency of HCV, then the associations between HCV and neurocognitive impairment observed in our study may be underestimated (ie, biased toward the null).
Our study offers a unique glimpse of the impact of HCV among individuals who may be cognitively and physically compromised by past cancer treatments. Our findings suggest that HCV-seropositive survivors of childhood cancer have a higher prevalence of neurocognitive impairment and reduced HRQOL in comparison with HCV-seronegative survivors, and both groups have been exposed to neurotoxic cancer therapies. In addition, our findings raise the awareness of a public health concern: adult survivors of childhood cancer, many of whom may be unaware of their exposure to blood products during the course of their cancer treatments, 41 may benefit from HCV screenings and education regarding the functional sequelae of HCV exposure. 
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